Press
Klaria publishes press releases—regulatory and non-regulatory—filterable by year.
Klaria Pharma Holding is a pharmaceutical company developing and licensing transmucosal alginate film drug delivery products to commercial partners.
klariapharma.seCrawled Nov 13, 2026
Klaria publishes press releases—regulatory and non-regulatory—filterable by year.
The page introduces Klaria’s leadership, including its founder and executives with pharmaceutical development backgrounds.
Klaria Pharma Holding AB is located at Virdings Allé 2, 754 50 Uppsala.
Klaria develops new medications using its alginate film, which adheres to the oral mucosa and delivers drugs directly into the bloodstream without swallowing.
Klaria Pharma Holding AB sets **6 November 2026** as the final day for subscribing to its rights issue, offering units worth up to **SEK 147.6 million**. Subscription via Vator Securities remains open until **15:00 CET** on that date, though some banks and nominees may enforce earlier deadlines.
Klaria Pharma Holding AB releases a digital Q&A session featuring CEO Scott Boyer and chairman Fredrik Hübinette. The session provides insights into the company’s strategic direction and leadership perspectives. No specific details about content or outcomes are disclosed in the announcement.
Klaria Pharma Holding AB expects significant milestone and royalty revenues from the upcoming European launch of **Sumatriptan Alginate Film (SAF)**, a migraine treatment licensed to **CNX Therapeutics**. The company’s Chairman, Fredrik Hübinette, discusses the product’s market potential in an interview with Investor Studios. SAF is already approved for sale, positioning Klaria to capitalize on commercialization efforts.
Klaria Pharma Holding AB reports that L.E.K Consulting estimates peak annual sales of its migraine treatment, **Sumatriptan Alginate Film (SAF)**, could reach approximately **$500 million**. The valuation highlights the commercial potential of Klaria’s lead product in the migraine therapy market.
Klaria Pharma secures up to **SEK 74.8 million** to expand its operations. The Uppsala-based company develops **oral-mucosa drug-delivery films**, including its flagship product, **Sumatriptan Alginate Film (SAF)**, a sumatriptan treatment for migraine that avoids tablets, nasal sprays, or injections. The alginate-based polymer platform enables rapid absorption of active substances.